GLPwatch

Testicular cytoprotective effect of glucagon like peptide-1 in diabetic rats involves inhibition of apoptosis, endoplasmic reticulum stress and activation of autophagy.

Gen Physiol Biophys · 2023

Last updated 2026-05-28

In a study on diabetic rats, the GLP-1 drug exenatide reduced harmful changes in testicular tissue and improved a process called autophagy. The drug was given to rats alongside diabetes, and researchers measured blood sugar, hormones, and specific markers in the testicles.

AI summary of the abstract below.

JournalGen Physiol Biophys, 2023
Citations5
Relative citation ratio1.06
NIH percentile53
Molecules
Conditions studied Type 2 Diabetes

Abstract

This study aimed to explore the possible cytoprotective effects of exenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in the testicles of diabetic rats. Exenatide has numerous advantageous properties in addition to its hypoglycemic effect. However, its impact on testicular tissue in diabetes needs more clarification. Therefore, rats were divided into control, exenatide-treated, diabetic and exenatide-treated diabetic groups. Blood glucose and serum levels of insulin, testosterone, pituitary gonadotropins and kisspeptin-1 were measured. Real-time PCR for beclin-1, p62, mammalian target of rapamycin (mTOR), and AMP-activated protein kinase (AMPK), were estimated in testicular tissue in addition to markers of oxidative stress, inflammation, and endoplasmic reticulum stress. Also, immuno-expression of protein P53, nuclear erythroid factor2 (Nrf2) and vimentin was conducted. Exenatide was able to attenuate diabetic toxic changes and enhance autophagy in testicular tissue. These results indicate the protective effect of exenatide against diabetic testicular dysfunction.

Verbatim abstract via PubMed 36896943 ↗